WEGOVY (semaglutide) tablets

WEGOVY (semaglutide) – reduced calorie diet and increased physical activity drug therapy in India.

WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity:
• To reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
• To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.

Source Details: Patient Information.
WEGOVY must always be used under the supervision of a Registered Medical Practitioner (RMP).

Access WEGOVY for adults with established CV disease and either obesity or overweight on a Named Patient Import Basis

IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to WEGOVY (semaglutide) for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).

For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 |  Mr. Neeraj: +91 9811 747 774.

Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.